Carmell Therapeutics

company

About

Carmell develops technology for producing biologically-active plastics from blood plasma for treating bone and connective tissue injuries.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$4M
Industries
Biotechnology,Health Care,Life Science,Medical Device,Therapeutics
Founded date
Jan 1, 2007
Number Of Employee
1 - 10
Operating Status
Active

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$6.40M
Carmell Therapeutics has raised a total of $6.40M in funding over 2 rounds. Their latest funding was raised on Jul 11, 2017 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 11, 2017 Series B $4M 2 Detail
Apr 18, 2011 Series A $2.40M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Carmell Therapeutics is funded by 2 investors. Newlin Investment Company and Keiretsu Forum are the most recent investors.
Investor Name Lead Investor Funding Round
Newlin Investment Company Series B
Keiretsu Forum Series B